RNLX(RNLX)
RNLX
7/6/26
RENALYTIX (RNLX)
Monday
7:00 PM
Thesis: The stock's significant decline in value and ongoing operational losses are raising concerns among investors about its long-term viability.
Revenue Outlook
What Moves the Stock
- 1Regulatory approvals for new diagnostic tests
- 2Partnership agreements with healthcare providers
- 3Reimbursement rates from insurance companies
- 4Market adoption rates of KidneyIntelX
- 5Diagnostic testing services - 100%
- 6AI-driven healthcare solutions
- 7Personalized medicine in chronic disease management
FY2024 Snapshot
- Revenue
- $2M
- Rev. Growth
- -32.7%
- Gross Margin
- 6.8%
- Op. Margin
- -1293%
- Net Margin
- -1462%
- Net Income
- $-33M
- NI Growth
- +26.6%
- EPS
- $-0.62
- 1Y Return
- -45.1%
RNLX Chart
My Notes
- "The market is increasingly cautious as we navigate through regulatory challenges and competitive pressures."
- Moat: Renalytix's proprietary technology offers a competitive edge, but the moat is vulnerable to rapid technological advancements.
- growth - Investors are likely attracted to the potential for rapid revenue growth in the healthcare diagnostics sector.
- Rising interest rates may increase the cost of capital for Renalytix, affecting its ability to finance R&D and operational expansion.
- Watch on earnings: Test volume growth rate, Average reimbursement per test, Regulatory approval timelines.
One Sentence Summary:
Renalytix: the story is balanced — regulatory approvals for new diagnostic tests.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.